Low-Dose Chemotherapy with Insulin (Insulin Potentiation Therapy) in Combination with H... - 0 views
www.ncbi.nlm.nih.gov/...PMC3357525
prostate cancer IPTLD low-dose chemotherapy cancer chemotherapy insulin potentiation therapy LDMC low-dose metronomic chemotherapy IPT
![](/images/link.gif)
-
The method of insulin potentiation therapy was empirically invented in 1930 from Mexican doctor D. Perez Garsia
- ...9 more annotations...
-
facilitates the transport of intra and extra cellular liquids which helps the organism to eliminate the toxic products
-
The increased number of insulin receptors on the tumor cell, in comparison to the normal one, allows the before mentioned 2 factors to act predominantly
-
Increased permeability after the insulin effect on the cellular membrane results in increased intracellular quantity of antitumor agents
-
have other endocrine effects: directly stimulates suprarenal gland to produce epinephrine and glucocorticoid hormones and stimulates ACTH secretion. These endocrine effects also have a positive influence on the regenerating processes
-
Insulin influences the intracellular metabolism of the tumor cell, which leads to increase of the number of cells in phase S, where they are with highly sensitive to specific chemotherapeutics.
-
After the first 6 IPT applications overall (groups A and B) response to treatment on PSA criteria shows partial effect and stabilization in 12 of 16 (75%) patients
-
After the 10th IPTLD application or 3 months after starting treatment, complete response, partial response, and stabilization were observed in 4 of 9 (66.6%), while in 3 of 9 (33.3%) was registered complete effect